Expertise in
8
conditions

Dr. Warren L. Robinson

Hematology Oncology | Hematology
1100 Grampian Blvd, 
Williamsport, PA 
Expertise in
8
conditions
1100 Grampian Blvd, 
Williamsport, PA 

Overview

Warren Robinson is a Hematologist Oncology specialist and a Hematologist practicing medicine in Williamsport, Pennsylvania.

Dr. Robinson is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Prostate Cancer.

He is actively involved in clinical research, participating in 29 clinical trials.

Specialties

Hematology Oncology
Hematology

Licenses

Internal Medicine in PA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
QualChoice
  • MEDICARE MAPD
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

1100 Grampian Blvd, Williamsport, PA 17701

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

29 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
View 9 Less Clinical Trials
Similar Doctors
Expertise in
7
conditions
Dr. Phuong L. Mai
Hematology Oncology
Expertise in
7
conditions
Dr. Phuong L. Mai
Hematology Oncology
Referral may be required

UPMC Hillman Cancer Center

1100 Grampian Boulevard, 
Williamsport, PA 
 (0.1 miles away)
272-289-9902
Languages Spoken:
English, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Phuong Mai is a Hematologist Oncology provider practicing medicine in Williamsport, Pennsylvania. Dr. Mai is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Li-Fraumeni Syndrome, Breast Cancer, Ovarian Cancer, Oophorectomy, and Salpingo-Oophorectomy. Dr. Mai is board certified in American Board Of Internal Medicine. Dr. Mai is currently accepting new patients.

Expertise in
56
conditions
Dr. Abdalla M. Sholi
Hematology Oncology
Expertise in
56
conditions
Dr. Abdalla M. Sholi
Hematology Oncology
Referral may be required

UPMC Hillman Cancer Center At UPMC Williamsport Divine Providence

1100 Grampian Boulevard, 
Williamsport, PA 
 (0.1 miles away)
570-979-4773
Languages Spoken:
English
See accepted insurances

Abdalla Sholi, MD, specializes in hematology oncology and medical oncology and is board-certified in medical oncology by the American Board of Internal Medicine. He is affiliated with UPMC Williamsport, UPMC Wellsboro and UPMC Cole. Dr. Sholi completed his residencies in primary care and internal medicine at Scranton-Temple Residency Program and medical degree at the University of Jordan. Dr. Sholi is highly rated in 56 conditions, according to our data. His clinical expertise encompasses Inflammatory Breast Cancer, Lung Cancer, Pleuropulmonary Blastoma, and Small Cell Lung Cancer (SCLC). Dr. Sholi is board certified in American Board Of Internal Medicine.

Expertise in
23
conditions
Dr. Eugene Muchnik
Hematology Oncology
Expertise in
23
conditions
Dr. Eugene Muchnik
Hematology Oncology
Referral may be required

UPMC Hillman Cancer Center At UPMC Williamsport Divine Providence

1100 Grampian Boulevard, 
Williamsport, PA 
 (0.1 miles away)
272-289-9253
Languages Spoken:
English, Russian
See accepted insurances

Eugene Muchnik, MD, specializes in hematology oncology and medical oncology and is board-certified in hematology, internal medicine and medical oncology by the American Board of Internal Medicine. He is affiliated with UPMC Wellsboro, UPMC Cole and UPMC Williamsport. Dr. Muchnik completed his fellowship and residency at Strong Memorial Hospital University of Rochester and medical degree at UMDNJ University Hospital. Dr. Muchnik is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Colorectal Cancer, Pleuropulmonary Blastoma, and Hemochromatosis. Dr. Muchnik is board certified in American Board Of Internal Medicine , American Board Of Internal Medicine , and American Board Of Internal Medicine.

Frequently Asked Questions about Dr. Warren L. Robinson

How do I make an appointment with Dr. Warren L. Robinson?

You can book an appointment with Dr. Warren L. Robinson by calling their office at 570-326-8470. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Warren L. Robinson a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Warren L. Robinson is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Warren L. Robinson specialize in?

While Dr. Warren L. Robinson is a Hematology Oncology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Warren L. Robinson accept my insurance?

Dr. Warren L. Robinson accepts most major insurance plans, including Aetna and QualChoice. We recommend calling the office directly at 570-326-8470 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Robinson's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 59 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile